Search

Your search keyword '"Lavi, Noa"' showing total 422 results

Search Constraints

Start Over You searched for: Author "Lavi, Noa" Remove constraint Author: "Lavi, Noa"
422 results on '"Lavi, Noa"'

Search Results

1. Irreducibility in generalized power series

4. 'We Only Teach Them How to Be Together': Parenting, Child Development, and Engagement with Formal Education among the Nayaka in South India

9. The generic pair conjecture for dependent finite diagrams

10. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

12. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

15. Positivstellens\'atze for semi-algebraic sets in real closed valued fields

16. A Ganzstellensatz for semi-algebraic sets and a boundedness criterion for rational functions

17. MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

18. POSTER: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

20. PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS

21. P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1

22. P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY

26. Data from Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy

27. Supplementary Data from Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy

35. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

36. Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

37. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

41. The Relationship Between Maintenance of Negative and Positive Affect in Working Memory and the Duration of the Affective Experience

42. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group

43. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study

47. Rewild your inner hunter-gatherer: how an idea about our ancestral condition is recruited into popular debate in Britain and Ireland

Catalog

Books, media, physical & digital resources